Breaking News Instant updates and real-time market news.

TRVN

Trevena

$1.80

0.2 (12.50%)

, TTPH

Tetraphase

$6.47

0.17 (2.70%)

17:29
01/02/18
01/02
17:29
01/02/18
17:29

On The Fly: After Hours Movers

HIGHER: Trevena (TRVN), up 20% after it announced FDA acceptance for review of OLINVO... Tetraphase (TTPH), up 5.9% after it submitted an FDA application for eravacycline in cIAI treatment. LOWER: MoneyGram (MGI), down 5% after it terminated its merger agreement with Ant Financial... Howard Hughes (HHC), down 3.3% after it filed to sell 2.5M shares of common stock... Sempra Energy (SRE), down 2.3% after it filed to sell $2.5B in common stock and after it cited the recent U.S. tax legislation among its risk factors.

TRVN

Trevena

$1.80

0.2 (12.50%)

TTPH

Tetraphase

$6.47

0.17 (2.70%)

MGI

MoneyGram

$13.31

0.13 (0.99%)

HHC

Howard Hughes

$132.84

1.43 (1.09%)

SRE

Sempra Energy

$105.35

-1.8025 (-1.68%)

  • 02

    Jan

  • 23

    Jan

  • 24

    Jan

  • 05

    Jan

TRVN Trevena
$1.80

0.2 (12.50%)

10/16/17
LEHM
10/16/17
DOWNGRADE
Target $2.5
LEHM
Equal Weight
Trevena downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded Trevena to Equal Weight and cut his price target for the shares to $2.50 from $15. The analyst says the downgrade reflects uncertainty in the commercial outlook for Olinvo. He sees a financing overhang and limited catalysts for the shares.
10/13/17
OPCO
10/13/17
NO CHANGE
Target $5
OPCO
Outperform
Trevena selloff yesterday likely overdone, says Oppenheimer
Oppenheimer analyst Derek Archila views Trevena's restructuring plan as a "smart move" with the company needing to conserve cash for an Olinvo approval/launch in the second half of 2018. The analyst continues to believe Olinvo for post-surgical pain will find its "niche" as a treatment for patients at high risk of opioid related adverse events. He views yesterday's 15% pullback as likely overdone and keeps an Outperform rating on Trevena. The analyst, though, cut his price target for the shares to $5 from $8.
02/23/17
HCWC
02/23/17
NO CHANGE
Target $8
HCWC
Buy
Trevena price target lowered to $8 from $11 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Trevena to $8 to reflect reduced expectations on Olinvo's commercial uptake following the Phase 3 readouts. The analyst does not believe commercial success is an "all-or-nothing" proposition, however, and keeps a Buy rating on the shares.
03/14/17
OPCO
03/14/17
NO CHANGE
Target $10
OPCO
Outperform
Trevena selloff overdone, says Oppenheimer
Oppenheimer analyst Derek Archila says that despite the company's mixed results relative to morphine, he believes the recent selloff is overdone and that Olinvo will be approved given its statistically significant results versus placebo. The analyst thinks Olinvo remains commercially viable given the trends on improved safety from the APOLLO studies, and should become an important option for patients most at risk for opioid-related adverse events. He reiterates an Outperform rating and $10 price target.
TTPH Tetraphase
$6.47

0.17 (2.70%)

10/05/17
BMOC
10/05/17
NO CHANGE
BMOC
Tetraphase price target raised to $24 from $13 at BMO Capital
BMO Capital analyst M. Ian Somaiya says Phase I data on the oral version of Tetraphase's eravacycline indicate that dose changes "and meal timing can effectively double drug exposure." The analyst says that the exposure levels of the oral treatment are now 80%-90% of the IV version. He raised his estimate of the oral version's chance of success to 33% from 25% and increased his price target on the shares to $24 from $13. He keeps an Outperform rating on the stock.
11/06/17
HCWC
11/06/17
NO CHANGE
Target $17
HCWC
Buy
Tetraphase price target raised to $17 from $15 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Tetraphase to $17 saying the six corporate milestones laid out in the Q3 earnings release "highlight several potential value-creating stock catalysts in 2018." The analyst believes the company is well positioned to achieve the milestones. He keeps a Buy rating on the shares.
10/18/17
PIPR
10/18/17
NO CHANGE
Target $14
PIPR
Overweight
Piper a buyer of Tetraphase after meeting with key opinion leader
After hosting a client lunch with Dr. Andrew Shorr from MedStar Washington Hospital Center and Georgetown University, Piper Jaffray analyst Edward Tenthoff say he remains a buyer of Tetraphase Pharmaceuticals. The doctor highlighted the need for new agents to treat ESBL-producing gram-negative infections in the hospital setting, Tenthoff tells investors in a research note. He sees a place for front-line use of Tetraphase's eravacycline as well as a destination therapy. The analyst recommends buying Tetraphase ahead of a "busy" Q1 of 2018 and reiterates an Overweight rating on the name with a $14 price target.
10/06/17
RHCO
10/06/17
NO CHANGE
Target $19
RHCO
Buy
Tetraphase oral eravacycline data 'encouraging,' says SunTrust
SunTrust analyst Edward Nash says the Phase I data on oral eravacycline to be presented by Tetraphase at tomorrow's IDWeek 2017 session "shows strong promise". Nash notes that optimized fasting period around the oral dosing regimen leads to improved performance of the treatment, suggesting the IGNITE2 failure may have been the result of suboptimal food effect. The analyst maintains a Buy rating on the stock with a $19 price target.
MGI MoneyGram
$13.31

0.13 (0.99%)

07/25/17
DADA
07/25/17
NO CHANGE
DADA
Euronet would benefit if Moneygram deal blocked, says DA Davidson
After media outlets reported that the U.S. government could block the acquisition of Moneygram (MGI) by Alibaba's (BABA) Ant Financial, DA Davidson analyst Peter Heckmann indicates that such a development would help Euronet (EEFT). He notes that Euronet previously made an unsuccessful bid for Moneygram. He believes that if Euronet is able to acquire Moneygram, the deal would be "transformational" and " would provide visibility to attractive revenue and earnings growth into 2020". Conversely, if Ant acquires Moneygram, Euronet and Western Union (WU) could come under increased pressure, the analyst stated. He keeps a Buy rating on Euronet. .
12/12/17
JPMS
12/12/17
DOWNGRADE
Target $13
JPMS
Underweight
MoneyGram downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tien-tsin Huang downgraded MoneyGram to Underweight and cut his price target for the shares to $13 from $18. It is more likely than not that the Ant Financial deal will be blocked by the Committee on Foreign Investment in the United States, Huang tells investors in a research note. He also believes weakness in trends year-to-date has likely hurt MoneyGram's standalone value.
03/14/17
BTIG
03/14/17
NO CHANGE
BTIG
BTIG says Western Union positive reaction to MoneyGram news makes sense
BTIG analyst Mark Palmer said he believes the uptick in Western Union (WU) shares after the announcement of Euronet's (EEFT) offer to buy competitor MoneyGram (MGI) makes some sense as Euronet may be seen as less of a competitive threat than Alibaba's (BABA) Ant Financial, which previously struck a deal to buy MoneyGram, and the bid underscores the attractiveness and potential of the global remittance space. However, speculation that if Ant was unsuccessful in its effort to acquire MoneyGram it could look to acquire VeriFone (PAY) or Green Dot (GDOT) "makes less sense," said Palmer.
03/14/17
RHCO
03/14/17
NO CHANGE
RHCO
Buy
SunTrust says buy Euronet on MoneyGram deal selloff
Euronet's (EEFT) $1.8B offer to acquire MoneyGram (MGI) is "superior in all ways" to Ant Financial's, which is owned by Alibaba (BABA), SunTrust analyst Andrew Jeffrey tells investors in a research note. He expects shares of Euronet to come under pressure this morning "as many investors simply do not like global remittance." Jeffrey recommends using the weakness to buy Euronet, however, as he feels the company has a differentiated franchise and superior management and growth strategy.
HHC Howard Hughes
$132.84

1.43 (1.09%)

03/30/17
SDLR
03/30/17
INITIATION
Target $123
SDLR
Hold
Howard Hughes initiated with a Hold at Sandler O'Neill
Sandler O'Neill analyst Alexander Goldfarb initiated Howard Hughes with a Hold and a $123 price target citing valuation and the late stage of the economic cycle.
06/08/17
BWSF
06/08/17
INITIATION
Target $150
BWSF
Buy
Howard Hughes initiated with a Buy at BWS Financial
BWS Financial analyst Hamed Khorsand initiated Howard Hughes with a Buy rating and $150 price target, saying he believes now is the time get involved with Houston starting to show signs of stability and its Seaport project becoming commercially ready.
06/08/17
BWSF
06/08/17
INITIATION
Target $150
BWSF
Buy
Howard Hughes initiated with a Buy at BWS Financial
BWS Financial analyst Vahid Khorsand started Howard Hughes with a Buy rating and $150 price target. With the Houston economy starting to show signs of stability, and Seaport commercially ready, now is the buy to buy the stock, the analyst tells investors in a research note.
SRE Sempra Energy
$105.35

-1.8025 (-1.68%)

12/22/17
BOFA
12/22/17
DOWNGRADE
Target $112
BOFA
Neutral
Sempra Energy downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin-Smith downgraded Sempra Energy to Neutral and cut its price target to $112 from $125 due to ongoing wildfire risk, which will be an overhang for the company. The analyst added the recent selloff in shares also puts pressure on the upcoming $6B equity raise and accretion metrics for Oncor.
06/08/17
LEHM
06/08/17
DOWNGRADE
Target $121
LEHM
Equal Weight
Sempra Energy downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Daniel Ford downgraded Sempra Energy (SRE) to Equal Weight with the shares close to his unchanged price target of $121. The analyst is increasingly concerned that the Cameron LNG export facility could face construction delays given the project's association with CB&I (CBI).
10/11/17
GSCO
10/11/17
UPGRADE
Target $129
GSCO
Buy
Sempra Energy upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Michael Lapides upgraded Sempra Energy to Buy and raised his price target for the shares to $129 from $117. Utility and infrastructure project developments in the U.S. and Mexico create an "active catalyst path" over the next six-to-nine months, Lapides tells investors in a research note. Further, the analyst believes the proposed acquisition of Energy Future Holdings could drive higher growth.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

HII

Huntington Ingalls

$242.12

5.24 (2.21%)

17:21
01/19/18
01/19
17:21
01/19/18
17:21
Hot Stocks
Huntington Ingalls awarded $125.2M government contract modification »

Huntington Ingalls Inc. -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 21

    Feb

BAESY

BAE Systems

$33.30

0.18 (0.54%)

, GD

General Dynamics

$209.10

1.3 (0.63%)

17:20
01/19/18
01/19
17:20
01/19/18
17:20
Hot Stocks
BAE Systems, General Dynamics awarded $237.6M government contract modification »

BAE Systems (BAESY) San…

BAESY

BAE Systems

$33.30

0.18 (0.54%)

GD

General Dynamics

$209.10

1.3 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SYRS

Syros Pharmaceuticals

$10.80

0.27 (2.56%)

17:17
01/19/18
01/19
17:17
01/19/18
17:17
Syndicate
Breaking Syndicate news story on Syros Pharmaceuticals »

Syros Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTFC

Wintrust Financial

$87.81

0.96 (1.11%)

17:13
01/19/18
01/19
17:13
01/19/18
17:13
Hot Stocks
Wintrust Financial raises its minimum wage to $15 per hour »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.66

-0.38 (-1.58%)

17:07
01/19/18
01/19
17:07
01/19/18
17:07
Hot Stocks
Twitter says has identified more IRA and automated Russia-based accounts »

In a statement on its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.